This application is submitted in response to the RFA for a Coordinating Center (CC) to serve the needs of the Diabetic Macular Edema Clinical Research Network. The network is expected to include 25 clinics, a Fundus Photograph Reading Center (FPRC), Study Chairman's Office, and a CC. The main objective of this network is to evaluate promising new treatment approaches for diabetic macular edema (DME). The role of the CC is critical for the success of a multi-center study. The importance to the network of having an experienced CC, particularly one with experience in eye disease trials, is sufficiently self-evident in the RFA that it needs no justification statements here. While the core principles followed by a CC in study protocol design, quality control, study conduct, and statistical analyses have changed little in the last 20 years, through technologic advances the approach to carrying out many CC functions has changed considerably. Advances in computing and in access to the Internet have provided new opportunities for a CC to enhance quality control measures and at the same time increase efficiency. This evolution in CC trial management will continue as technology continues to advance. For essentially all aspects of the project, we will draw upon our experience in our past and current studies. We have coordinated numerous multi-center eye disease investigator groups and have experience with all of the CC functions and responsibilities that will be part of this project. We have considerable experience with study groups conducting multiple, concurrent and consecutive protocols, a likely aspect of this project. We have been innovative in our approach to clinical trial conduct and management and have relied extensively on using the Internet to not only increase efficiency but also in many ways to enhance quality control measures. For a number of years we have worked to develop a data management system that is as generic as possible so a new study can be readily added to an existing data management structure. This extends to website development in which the web-based applications we have developed for our prior and current studies will serve as a template for this project. This proposal will detail the capabilities of the Jaeb Center to serve as the CC for the network and our plans to carry out the objectives of the project.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10EY014231-03
Application #
6740114
Study Section
Special Emphasis Panel (ZEY1-VSN (03))
Program Officer
Miskala, Paivi
Project Start
2002-09-30
Project End
2008-12-31
Budget Start
2004-02-01
Budget End
2004-12-31
Support Year
3
Fiscal Year
2004
Total Cost
$3,467,849
Indirect Cost
Name
Jaeb Center for Health Research, Inc.
Department
Type
DUNS #
957043193
City
Tampa
State
FL
Country
United States
Zip Code
33647
Glassman, Adam R; Liu, Danni; Jampol, Lee M et al. (2018) Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. Invest Ophthalmol Vis Sci 59:1199-1205
Wang, Tiansheng; Hong, Jin-Liern; Gower, Emily W et al. (2018) Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults. Diabetes Care 41:1998-2009
Wells, John A; Glassman, Adam R; Ayala, Allison R et al. (2017) Reply. Ophthalmology 124:e5-e6
Beaulieu, Wesley T; Bressler, Neil M; Melia, Michele et al. (2016) Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial. Am J Ophthalmol 170:206-213
Wells, John A; Glassman, Adam R; Ayala, Allison R et al. (2016) Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology 123:1351-9
Bressler, Susan B; Glassman, Adam R; Almukhtar, Talat et al. (2016) Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema. Am J Ophthalmol 164:57-68
Gross, Jeffrey G; Glassman, Adam R (2016) A Novel Treatment for Proliferative Diabetic Retinopathy: Anti-Vascular Endothelial Growth Factor Therapy. JAMA Ophthalmol 134:13-4
Bressler, Susan B; Ayala, Allison R; Bressler, Neil M et al. (2016) Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment. JAMA Ophthalmol 134:278-85
Jampol, Lee M; Glassman, Adam R; Bressler, Neil M et al. (2016) Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial. JAMA Ophthalmol 134:
Wells, John A; Glassman, Adam R; Jampol, Lee M et al. (2016) Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. JAMA Ophthalmol 134:127-34

Showing the most recent 10 out of 69 publications